Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Operations: 2016-2024

Historic Cash from Operations for Arcus Biosciences (RCUS) over the last 9 years, with Dec 2024 value amounting to -$170.0 million.

  • Arcus Biosciences' Cash from Operations fell 473.08% to -$97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$462.0 million, marking a year-over-year decrease of 192.41%. This contributed to the annual value of -$170.0 million for FY2024, which is 44.44% up from last year.
  • Latest data reveals that Arcus Biosciences reported Cash from Operations of -$170.0 million as of FY2024, which was up 44.44% from -$306.0 million recorded in FY2023.
  • Arcus Biosciences' 5-year Cash from Operations high stood at $438.0 million for FY2022, and its period low was -$306.0 million during FY2023.
  • For the 3-year period, Arcus Biosciences' Cash from Operations averaged around -$12.7 million, with its median value being -$170.0 million (2024).
  • As far as peak fluctuations go, Arcus Biosciences' Cash from Operations plummeted by 330.63% in 2021, and later soared by 271.09% in 2022.
  • Arcus Biosciences' Cash from Operations (Yearly) stood at $111.0 million in 2020, then plummeted by 330.63% to -$256.0 million in 2021, then soared by 271.09% to $438.0 million in 2022, then crashed by 169.86% to -$306.0 million in 2023, then soared by 44.44% to -$170.0 million in 2024.